Cumberland Pharmaceuticals (NASDAQ:CPIX) announced its quarterly earnings data on Wednesday. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.01), Yahoo Finance reports. The business had revenue of $8.33 million during the quarter, compared to the consensus estimate of $9.46 million. Cumberland Pharmaceuticals had a negative net margin of 10.28% and a positive return on equity of 3.74%.
Shares of CPIX opened at $3.54 on Friday. The stock’s 50-day simple moving average is $3.86 and its 200 day simple moving average is $4.53. The stock has a market capitalization of $54.35 million, a price-to-earnings ratio of 32.54 and a beta of 0.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.69 and a current ratio of 2.08. Cumberland Pharmaceuticals has a 52-week low of $3.32 and a 52-week high of $6.74.
CPIX has been the subject of several research reports. TheStreet downgraded Cumberland Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Friday, March 13th. B. Riley reiterated a “buy” rating on shares of Cumberland Pharmaceuticals in a research note on Thursday, March 19th. Finally, Zacks Investment Research downgraded Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday.
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Read More: Profit margin is different from the revenue
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.